Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 38, 2014, Pages 13906-13911

  Komarova, Natalia L ^a   Burger, Jan A ^b   Wodarz, Dominik ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Drug resistance; Evolutionary dynamics; Mathematical models; Personalized medicine; Stochastic dynamics

Indexed keywords

AGAMMAGLOBULINAEMIA TYROSINE KINASE; IBRUTINIB; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUMOR PROTEIN;

ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MOLECULAR EVOLUTION; MUTATION; PROGNOSIS;

DRUG RESISTANCE, NEOPLASM; EVOLUTION, MOLECULAR; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MODELS, BIOLOGICAL; MUTATION; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84907284539     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1409362111     Document Type: Article

References (39)

1. Burger JA, Chiorazzi N (2013) B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 34(12):592-601.
2. Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352(8):804-815.
3. Pan Z, et al. (2007) Discovery of selective irreversible inhibitors for Bruton. The s tyrosine kinase. ChemMedChem 2(1):58-61.
4. Honigberg LA, et al. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks Bcell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107(29):13075-13080.
5. Burger JA, Buggy JJ (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 54(11):2385-2391.
6. Advani RH, et al. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31(1):88-94.
7. Byrd JC, et al. (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369(1):32-42.
8. Wang ML, et al. (2013) Targeting BTK with ibrutinib in relapsed or refractory mantlecell lymphoma. N Engl J Med 369(6):507-516.
9. Herman SE, et al. (2011) Bruton. The s tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117(23):6287-6296.
10. Ponader S, et al. (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5):1182-1189.
11. de Rooij MF, et al. (2012) The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119(11):2590-2594.
12. Burger JA, Buggy JJ (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 54(11):2385-2391.
13. Chang BY, et al. (2013) Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL). 2013 ASCO Meeting Abstracts, Abstract no. 7014.
14. Furman RR, et al. (2014) Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med 370(24):2352-2354.
15. Woyach JA, et al. (2014) Resistance mechanisms for the Bruton. The s tyrosine kinase inhibitor ibrutinib. N Engl J Med 370(24):2286-2294.
16. Messmer BT, et al. (2005) In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 115(3):755-764.
17. Wodarz D, et al. (2014) Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood 123(26):4132-4135.
18. Alberts B, et al. (2013) Essential Cell Biology (Garland Science, New York).
19. Calabrese P, Shibata D (2010) A simple algebraic cancer equation: Calculating how cancers may arise with normal mutation rates. BMC Cancer 10:3.
20. Sverdlov ED, Mineev K (2013) Mutation rate in stem cells: An underestimated barrier on the way to therapy. Trends Mol Med 19(5):273-280.
21. Tomlinson I, Sasieni P, Bodmer W (2002) How many mutations in a cancer? Am J Pathol 160(3):755-758.
22. Tomlinson IP (2001) Mutations in normal breast tissue and breast tumours. Breast Cancer Res 3(5):299-303.
23. Komarova NL, Wodarz D (2005) Drug resistance in cancer: Principles of emergence and prevention. Proc Natl Acad Sci USA 102(27):9714-9719.
24. Tipping AJ, Mahon FX, Lagarde V, Goldman JM,Melo JV (2001) Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood 98(13):3864-3867.
25. Gorre ME, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531):876-880.
26. Byrd JC, et al.; RESONATE Investigators (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371(3):213-223.
27. Byrd JC, et al. (2012) The Bruton. The s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naive (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: Newand updated results of 116 patients in a phase Ib/II study. 54th Annual ASH Meeting and Exposition, no. 189.
28. O.Brien S, et al. (2014) Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 15(1):48-58.
29. Woyach JA, et al. (2014) Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients. J Clin Oncol 32:5s (suppl; abstr 7010).
30. Rossi D, Gaidano G (2014) Lymphocytosis and ibrutinib treatment of CLL. Blood 123(12):1772-1774.
31. Woyach JA, et al. (2014) Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 123(12):1810-1817.
32. Del Monte U (2009) Does the cell number 10(9) still really fit one gram of tumor tissue? Cell Cycle 8(3):505-506.
33. Komarova NL, Wu L, Baldi P (2007) The fixed-size Luria-Delbruck model with a nonzero death rate. Math Biosci 210(1):253-290.
34. Furman RR, et al. (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370(11):997-1007.
35. Luebeck EG, Moolgavkar SH (2002) Multistage carcinogenesis and the incidence of colorectal cancer. Proc Natl Acad Sci USA 99(23):15095-15100.
36. Rodriguez-Brenes IA, Komarova NL, Wodarz D (2013) Tumor growth dynamics: Insights into evolutionary processes. Trends Ecol Evol 28(10):597-604.
37. Frank SA (2007) Dynamics of Cancer: Incidence, Inheritance, and Evolution (Princeton Univ Press, Princeton, NJ).
38. Komarova NL, Wodarz D (2013) Trageted Treatment in Silico: Small Molecule Inhibitors and ONcolytic Viruses (Birkhäuser, New York).
39. Wodarz D, Komarova NL (2014) Dynamics of Cancer: Mathematical Foundations of Oncology (World Scientific Publishing, London).